GRIFOLS LOGO
Intended for US Residents Only
Xembify logo
Home icon

Welcome to XEMBIFY Patient Speaker Programs Online Registration

Join us for a free, educational program (webinar) for patients with primary humoral immunodeficiency disease (PI) and their caregivers where you’ll hear from trained nurses.

RegisterProgramLocationSpeakers
XEMBIFY Patient Speaker Program
Wednesday, June 26, 2024
8:00pm EST
Virtual ProgramAndrea Roberts, RN, MSN, NP, IgCN
XEMBIFY Patient Speaker Program
Thursday July 11, 2024
7:30pm EST
Virtual ProgramAlexandra Baker, BSN, RN
XEMBIFY Patient Speaker Program
Wednesday July 17, 2024
7:30pm EST
Virtual ProgramLaura Smith BSN, RN, IgCN
XEMBIFY Patient Speaker Program
Thursday, July 25, 2024
6:00pm EST
In-Person Dinner Program
Location To Be Announced
Philadelphia, PA
Alexandra Baker, BSN, RN
XEMBIFY Patient Speaker Program
Thursday, August 15, 2024
7:30pm EST
Virtual ProgramRikki Mensch, MBA, BSN RN, IgCN
XEMBIFY Patient Speaker Program
Tuesday, August 27, 2024
8:00pm EST
Virtual ProgramDebbie Manning, BSN, RN, IgNS
XEMBIFY Patient Speaker Program
Thursday, September 12, 2024
7:30pm EST
Virtual ProgramMichelle Springfield, MHA, RN, IgCN
XEMBIFY Patient Speaker Program
Thursday, September 19, 2024
6:00pm EST
In-Person Dinner Program
Location To Be Announced
Boston, MA
Gina Livingston MSN, FNP-BC, NP-C, RN, IgCN
XEMBIFY Patient Speaker Program
Saturday, September 28, 2024
12:00pm EST
Virtual ProgramGina Livingston MSN, FNP-BC, NP-C, RN, IgCN
XEMBIFY Patient Speaker Program
Saturday, November 9, 2024
12:30pm CDT
In-Person Lunch Program
Location To Be Announced
Dallas, TX
Michelle Springfield, MHA, RN, IgCN

Do you have questions about XEMBIFY? 
Click here for more information.

What is XEMBIFY®?

XEMBIFY® (immune globulin subcutaneous human–klhw) is a 20% immune globulin used in the treatment of primary humoral immunodeficiency disease (PIDD) in patients 2 years of age and older. XEMBIFY is for subcutaneous administration only.

Important Safety Information

WARNING: THROMBOSIS

  • Thrombosis (formation of blood clots within blood vessels) may occur with immune globulin products, including XEMBIFY. Before you take XEMBIFY, talk to your doctor if you:
    • Are older
    • Are sedentary (need to lie down or sit down) for long periods of time
    • Are taking estrogen-containing medicines (birth control pills, hormone replacement therapy)
    • Have a permanent intravenous (IV) catheter
    • Have hyperviscosity of the blood (diseases such as multiple myeloma or other causes of elevated proteins in the blood)
    • Have cardiovascular (heart) problems or previous history of stroke
    • Thrombosis may occur even if you don’t have any risk factors
  • Thrombosis may occur even if you don't have any risk factors
  • If you are at risk of thrombosis, your doctor may prescribe XEMBIFY at the minimum dose and infusion rate. Make sure you drink plenty of fluid before taking XEMBIFY. Make sure your doctor is checking you regularly for signs and symptoms of thrombosis and is checking your blood viscosity if you are at risk of hyperviscosity

Who should not use XEMBIFY?

  • XEMBIFY should not be used if you have had a severe allergic reaction to human immune globulin, or if you have been told by a doctor that you are IgA deficient and have developed antibodies to IgA and hypersensitivity after exposure to a previous plasma product

What are possible serious side effects of XEMBIFY?

  • Hypersensitivity. Severe allergic reactions may occur with immune globulin products, including XEMBIFY. If you have a severe allergic reaction, stop the infusion immediately and get medical attention. XEMBIFY contains IgA. If you have known antibodies to IgA, you may have a greater risk of developing potentially severe allergic reactions
  • Aseptic meningitis syndrome (AMS). Aseptic meningitis is a non-infectious inflammation of the membranes that cover the brain. It causes a severe headache syndrome, which may occur with human immune globulin treatment, including XEMBIFY. If you are showing signs and symptoms of AMS, your doctor may conduct a thorough neurological evaluation including spinal tap (sampling fluid which surrounds the spinal cord) to rule out other causes of meningitis. Stopping human immune globulin treatment has resulted in the end of signs and symptoms within several days. Treatment may include analgesics (pain medicines) and/or a special procedure known as a “blood patch” to stop headache
  • Kidney problems or failure. Kidney problems or failure may occur with use of human immune globulin products, especially those containing sucrose (sugar). XEMBIFY does not contain sucrose. If you have kidney disease or diabetes with kidney involvement, your doctor should perform a blood test to assess your hydration level and kidney function before beginning immune globulin treatment and at appropriate intervals thereafter. If your doctor determines that kidney function is worsening, they may discontinue treatment
  • Hemolysis. Your doctor should monitor you for symptoms of hemolysis (destruction of red blood cells causing anemia, or low red blood cell count). If your doctor suspects hemolysis, they should perform additional tests to confirm
  • Transfusion-related acute lung injury (TRALI). TRALI is a rare but serious syndrome characterized by sudden acute respiratory distress following transfusion. If your doctor suspects TRALI, they will monitor you for any other lung issues. TRALI may be managed with oxygen therapy
  • Transmissible infectious agents. Because XEMBIFY is made from human blood, it may carry a risk of transmitting infectious agents such as viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt- Jakob disease (CJD) agent. No cases of transmission of viral diseases or CJD have been associated with the use of XEMBIFY
  • Interference with lab tests. Because XEMBIFY contains a variety of antibodies, blood tests to determine antibody levels may be falsely elevated. Be sure to tell your doctor or lab technician that you are using XEMBIFY

What are other possible side effects of XEMBIFY?

  • In clinical studies of XEMBIFY, some patients experienced local side effects (at the injection site) including pain, redness, puffiness, bruising, nodules, itching, firmness, scabbing and swelling at the site on the skin where the injection occurred. Some patients experienced non-injection-site side effects including cough and diarrhea.
  • Use of XEMBIFY may interfere with the immune response to virus vaccines, such as vaccines for measles, mumps, rubella and varicella. Tell your doctor you are taking XEMBIFY before getting vaccinations

Please see full Prescribing Information for XEMBIFY.

About the Programs

During this informative session, a nurse will share information and insights for patients, caregivers, and families. These educational programs offer you and your family members or caregivers the opportunity to:

  • Learn more about PI and the role of XEMBIFY as a treatment option
  • Understand the process of self-administering XEMBIFY from a trained nurse
  • Learn ways to thrive with PI by leveraging educational resources and patient program support
To register over the phone, please contact: 1-800-223-5731 x566 or grifolsmeetings@medicalleverage.com
These programs are an educational support service for people living with PI. A caregiver or friend is welcome to join you for the session. The program and the speakers who participate in the program are sponsored by Grifols.​
www.grifols.com

© 2023 Grifols All rights reserved
October 2023. US-XEM-2300098

crossmenu